Product Description
Cerlapirdine is a Wyeth/Pfizer selective 5-HT6 receptor antagonist for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7356)
Mechanisms of Action: 5-HT6 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease
Phase 1: Alzheimer Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 3193A1-1103 | P1 |
Completed |
Healthy Volunteers |
2011-03-01 |
2019-03-19 |
Treatments |
|
| 3193A1-1109 | P1 |
Completed |
Alzheimer Disease |
2009-12-01 |
2019-03-19 |
Treatments |
|
| 3193A1-1114 | P1 |
Completed |
Alzheimer Disease |
2009-08-01 |
2019-03-18 |
||
| 3193A1-1111 | P1 |
Completed |
Alzheimer Disease |
2009-02-01 |
2019-03-18 |
||
| 3193A1-1112 | P1 |
Completed |
Alzheimer Disease |
2008-12-01 |
2019-03-18 |
Treatments |
|
| 3193A1-1110 | P1 |
Completed |
Alzheimer Disease |
2008-03-01 |
2019-03-21 |
Treatments |
|
| 3193A1-1104 | P1 |
Completed |
Alzheimer Disease |
2008-01-01 |
2019-03-21 |
Treatments |
|
| 3193A1-101 | P1 |
Completed |
Alzheimer Disease |
2007-02-01 |
2019-03-21 |
Treatments |
|
| 3193A1-102 | P1 |
Completed |
Alzheimer Disease |
None |
2019-03-21 |
Treatments |
|
| 3193A1-100 | P1 |
Completed |
Alzheimer Disease |
None |
2019-03-21 |
Treatments |
|
| JapicCTI-101240 | P2 |
Completed |
Alzheimer Disease |
2011-11-30 |
|||
| 3193A1-2005 | P2 |
Terminated |
Alzheimer Disease |
2011-05-01 |
2019-03-18 |
Treatments |
|
| 3193A1-2000 | P2 |
Completed |
Alzheimer Disease |
2008-01-01 |
2019-03-21 |
Treatments |